Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang, Lin Wang, Weihua Zhang, Huilai Zhang, Liping Xie, Ming Jiang, Hui Zhou, Yue-Rong Shuang, Hang Su, Xiaoyan Ke, Chuan Jin, Xin Du, Li Liu, Yaming Xi, Zheng Ge, Ru Feng, Yang Zhang, Shengyu Zhou, Fan Xie, Qian WangJournal of Hematology & Oncology 2021 · DOI

Abstract

This clinical trial (NCT03502629, registered April 18, 2018) investigated the efficacy and safety of geptanolimab (GB226), a novel anti-PD-1 antibody, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In this multicenter Phase 2 study, geptanolimab demonstrated a promising objective response rate (ORR) of 40.4% and a manageable safety profile, particularly in patients with high PD-L1 expression.

Introduction

Peripheral T-cell lymphoma (PTCL) represents a heterogeneous and aggressive group of non-Hodgkin lymphomas characterized by poor clinical outcomes. While frontline chemotherapy regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) are standard, a significant proportion of patients experience relapse or refractory disease. For these individuals, second-line treatment options are limited, often yielding response rates below 30%.

The application of immune checkpoint inhibitors, specifically anti-PD-1 antibodies, has been transformative in many malignancies. However, their utility in T-cell lymphomas has remained controversial due to concerns that PD-1 blockade might inadvertently accelerate disease progression—a phenomenon known as hyperprogression—in certain T-cell subtypes. The Gxplore-002 study was designed to evaluate the clinical potential of geptanolimab in this challenging patient population.

Methods

Gxplore-002 was a single-arm, multicenter Phase 2 clinical trial conducted across 41 sites in China. The study enrolled 102 patients with relapsed or refractory PTCL. Participants received geptanolimab at a dose of 3 mg/kg intravenously every two weeks.

The primary efficacy endpoint was the Objective Response Rate (ORR), determined by an Independent Radiological Review Committee (IRRC) using the Lugano 2014 criteria. Secondary analyses included biomarker evaluations of PD-L1 expression (via immunohistochemistry), Tumor Mutation Burden (TMB), and Microsatellite Instability (MSI) to identify predictors of therapeutic response.

Results

Efficacy and Survival

Of the 102 patients enrolled, 89 were included in the Full Analysis Set (FAS) following central histological confirmation. The IRRC-assessed ORR was 40.4% (95% CI: 30.2–51.4), comprising 13 complete responses (14.6%) and 23 partial responses (25.8%).

The median duration of response (DOR) was 11.4 months, indicating that responses to geptanolimab are often durable. For the entire FAS cohort, the median Progression-Free Survival (PFS) was 2.7 months, and the median Overall Survival (OS) reached 14.6 months.

Biomarker Correlation and Subtype Sensitivity

A key finding of the study was the significant correlation between PD-L1 expression and clinical benefit. Patients with high PD-L1 expression (≥ 50%) achieved an ORR of 53.3%, compared to 25.0% in the low-expression group. Furthermore, the median PFS in the PD-L1 high group was extended to 6.2 months.

Response rates also varied by PTCL subtype. Notably, patients with extranodal NK/T-cell lymphoma (ENKTL) showed a high sensitivity to geptanolimab, with an ORR of 63.2%.

Safety Profile

Geptanolimab demonstrated a manageable safety profile. Treatment-related adverse events (TRAEs) of Grade 3 or higher occurred in 25.5% of the safety population (n=102), primarily manifesting as hematological toxicities such as decreased white blood cell or platelet counts. While serious adverse events (SAEs) occurred in 44.1% of patients, only 18.6% were attributed to the study drug. Importantly, the trial did not observe widespread hyperprogressive disease, addressing a major concern regarding PD-1 inhibition in T-cell lymphomas.

Discussion

The Gxplore-002 study provides robust evidence that geptanolimab is an effective and safe option for patients with relapsed or refractory PTCL. The high response rates in the ENKTL subtype and the strong predictive value of PD-L1 expression (≥ 50%) offer a clear strategy for patient selection in clinical practice.

Despite these positive results, the study has limitations, including its single-arm design and relatively short median follow-up (4.06 months). Additionally, as the trial was conducted exclusively in China, further global studies are necessary to validate these findings across different geographic populations where PTCL subtype prevalence may differ.

Conclusion

Geptanolimab (GB226) represents a significant advancement in the immunotherapy landscape for r/r PTCL. Future randomized controlled trials with extended follow-up are warranted to further define its role in the standard of care for this aggressive disease.

Summary updated

Abstract

This clinical trial was registered at the ClinicalTrials.gov (NCT03502629) on April 18, 2018.
BibTeX
@article{shi2021efficacy,
  author = {Yuankai Shi and Jianqiu Wu and Zhen Wang and Liling Zhang and Zhao Wang and Mingzhi Zhang and Hong Cen and Zhigang Peng and Yufu Li and Lei Fan and Ye Guo and Liping Ma and Jie Cui and Yuhuan Gao and Haiyan Yang and Hongyu Zhang and Lin Wang and Weihua Zhang and Huilai Zhang and Liping Xie and Ming Jiang and Hui Zhou and Yue-Rong Shuang and Hang Su and Xiaoyan Ke and Chuan Jin and Xin Du and Xin Du and Li Liu and Yaming Xi and Zheng Ge and Ru Feng and Yang Zhang and Shengyu Zhou and Fan Xie and Qian Wang},
  title = {{Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)}},
  journal = {Journal of Hematology \& Oncology},
  year = {2021},
  doi = {10.1186/s13045-021-01033-1},
}
Figure